Bacterial Conjunctivitis – Pipeline Review, H2 2011

Document Sample
Bacterial Conjunctivitis – Pipeline Review, H2 2011 Powered By Docstoc
					Bacterial Conjunctivitis – Pipeline Review, H2 2011




      Bacterial Conjunctivitis – Pipeline Review, H2 2011


                                                                                          Reference Code: GMDHC1605IDB
                                                                                          Publication Date: December 2011




Bacterial Conjunctivitis – Pipeline Review, H2 2011                                       GMDHC1605IDB / Pub December 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                            Page(1)
Bacterial Conjunctivitis – Pipeline Review, H2 2011




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 3
    List of Figures ................................................................................................................................................................................ 4
Introduction......................................................................................................................................................................................... 5
    Global Markets Direct Report Coverage ........................................................................................................................................ 5
Bacterial Conjunctivitis Overview ....................................................................................................................................................... 6
Therapeutics Development................................................................................................................................................................. 7
    An Overview of Pipeline Products for Bacterial Conjunctivitis ....................................................................................................... 7
Bacterial Conjunctivitis Therapeutics under Development by Companies .......................................................................................... 9
Mid Clinical Stage Products.............................................................................................................................................................. 10
    Comparative Analysis .................................................................................................................................................................. 10
Discovery and Pre-Clinical Stage Products ...................................................................................................................................... 11
    Comparative Analysis .................................................................................................................................................................. 11
Bacterial Conjunctivitis Therapeutics – Products under Development by Companies...................................................................... 12
Companies Involved in Bacterial Conjunctivitis Therapeutics Development..................................................................................... 13
    Alcon, Inc. .................................................................................................................................................................................... 13
    InSite Vision Incorporated ........................................................................................................................................................... 14
    NovaBay Pharmaceuticals, Inc. ................................................................................................................................................... 15
Bacterial Conjunctivitis – Therapeutics Assessment ........................................................................................................................ 16
    Assessment by Monotherapy Products ....................................................................................................................................... 16
    Assessment by Combination Products ........................................................................................................................................ 17
    Assessment by Route of Administration ...................................................................................................................................... 18
    Assessment by Molecule Type .................................................................................................................................................... 20
Drug Profiles..................................................................................................................................................................................... 22
    AzaSite Xtra - Drug Profile .......................................................................................................................................................... 22
         Product Description................................................................................................................................................................. 22
         Mechanism of Action ............................................................................................................................................................... 22
         R&D Progress ......................................................................................................................................................................... 22
    NVC-422 - Drug Profile ................................................................................................................................................................ 23
         Product Description................................................................................................................................................................. 23
         Mechanism of Action ............................................................................................................................................................... 23
         R&D Progress ......................................................................................................................................................................... 23
    AL-15469A + AL-6515 - Drug Profile ........................................................................................................................................... 25
         Product Description................................................................................................................................................................. 25
         Mechanism of Action ............................................................................................................................................................... 25
         R&D Progress ......................................................................................................................................................................... 25
    NVC-727 - Drug Profile ................................................................................................................................................................ 26
         Product Description................................................................................................................................................................. 26
         Mechanism of Action ............................................................................................................................................................... 26
         R&D Progress ......................................................................................................................................................................... 26
    NVC-638 - Drug Profile ................................................................................................................................................................ 27
         Product Description................................................................................................................................................................. 27



Bacterial Conjunctivitis – Pipeline Review, H2 2011                                                                                       GMDHC1605IDB / Pub December 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Bacterial Conjunctivitis – Pipeline Review, H2 2011



         Mechanism of Action ............................................................................................................................................................... 27
         R&D Progress .................................................................
				
DOCUMENT INFO
Description: Bacterial Conjunctivitis – Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Bacterial Conjunctivitis - Pipeline Review, H2 2011', provides an overview of the Bacterial Conjunctivitis therapeutic pipeline. This report provides information on the therapeutic development for Bacterial Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bacterial Conjunctivitis. 'Bacterial Conjunctivitis - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Bacterial Conjunctivitis. - A review of the Bacterial Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bacterial Conjunctivitis pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Bacterial Conjunctivitis. - Identify emerging
BUY THIS DOCUMENT NOW PRICE: $500 100% MONEY BACK GUARANTEED
PARTNER GlobalMarketsDirect
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. Global Markets Direct has a broad range of coverage over key market segments. It has a global scope, covering a broad range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries